0QLR.IL - NOVARTIS AG NOVARTIS ORD SHS

IOB - IOB Delayed price. Currency in CHF
91.02
-0.11 (-0.12%)
As of 1:25PM GMT. Market open.
Stock chart is not supported by your current browser
Previous close91.13
Open91.21
Bid0.00 x N/A
Ask0.00 x N/A
Day's range90.80 - 91.32
52-week range83.15 - 102.63
Volume11,378
Avg. volume675,405
Market capN/A
Beta (3Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Investing.com

    Top 5 Things to Know in the Market on Tuesday

    Investing.com -- More happy talk from China on trade, while Fed Chairman Jerome Powell sees the economy's glass as "more than half full" (so no more rate cuts for now). Elsewhere, eBay keeps up the flurry of M&A; activity and the UN takes a swipe at countries for failing to live up to their Paris Accord pledges. Here's what you need to know in financial markets on Tuesday, 26th November.

  • Reuters

    Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin

    (Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of ...

  • Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript
    Motley Fool

    Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript

    LGND earnings call for the period ending December 31, 2018.

  • Reuters

    Novartis CEO lauds Trump administration plan to overhaul rebates

    Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines..

  • Novartis CEO says U.S. rebate plan will return cash to patients
    Reuters

    Novartis CEO says U.S. rebate plan will return cash to patients

    Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines.

  • Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript
    Motley Fool

    Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript

    ARRY earnings call for the period ending December 31, 2018.

  • Novartis's Alcon eye-care unit to enter Swiss index after spin off
    Reuters

    Novartis's Alcon eye-care unit to enter Swiss index after spin off

    Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland's 20 largest listed companies, market operator SIX said on Tuesday. Information about any other changes to SMI and Switzerland's other indexes will be released later, the bourse said. Novartis last year announced the spin off of Alcon to the Basel drugmaker's shareholders in the first half of this year.

  • Reuters - UK Focus

    LIVE MARKETS-Closing snapshots: Luxury, Serenity and Pleasure

    * European stocks inch up as trade talks loom * LVMH jumps, driving luxury stocks up * Apple, Boeing lift Wall Street ahead of Fed decision Jan 30 - Welcome to the home for real-time coverage of European ...

  • Reuters

    Novartis CEO sees 'further conversation' on Sandoz future in 18 months

    Novartis Chief Executive Vas Narasimhan said he will be ready to discuss the future of generics unit Sandoz following a revamp due to take 18 months, while still calling the business "an integral part" of the Swiss drugmaker. "We consider Sandoz an integral part of Novartis, we're focused on transforming the business, making it an autonomous entity over the next 18 months that is able to compete as an independent unit within Novartis," Narasimhan said on a call with analysts on Wednesday.

  • Reuters - UK Focus

    Drugmaker Sanofi says it is "as ready as can be" for Brexit

    Sanofi (LSE: 0O59.L - news) has nearly completed its preparations for Britain's planned exit from the European Union and is confident its additional stockpiling of medicines and other measures will prevent shortages for patients in the country. British Prime Minister Theresa May was on a collision course with the EU on Wednesday after lawmakers demanded she renegotiate a Brexit divorce deal that the other members of the bloc said they would not reopen. Last week, Switzerland's Novartis (IOB: 0QLR.IL - news) called on the British government to urgently guarantee the movement of drugs in the event of a chaotic Brexit and said it was stockpiling to maintain deliveries.

  • Novartis 2019 growth outlook leaves investors wanting more
    Reuters

    Novartis 2019 growth outlook leaves investors wanting more

    Novartis's 2019 sales and profit growth guidance disappointed investors seeking more from Chief Executive Vas Narasimhan's efforts to focus the Swiss drugmaker on high-tech medicines while shedding non-core assets. The company sees net sales growing by a low- to mid-single-digit percentage, with core operating income up by a mid-single-digit rate, Novartis said on Wednesday. Shares in the world's biggest prescription drugmaker had slipped 1.1 percent by 1305 GMT, lagging a 0.2 percent decline in the Stoxx European Health Care Index.

  • Reuters - UK Focus

    LIVE MARKETS-Got legs?

    * European stocks inch up as trade talks loom * LVMH jumps, driving luxury stocks up * Lonza tumbles after sales miss, CEO retiring * Atos leads STOXX 600 after results Jan 30 - Welcome to the home for ...

  • Reuters - UK Focus

    LIVE MARKETS-Q4 earnings meltdown: liked the data? See the graphic!

    * European stocks steady as trade talks loom * LVMH jumps, driving luxury stocks up * Lonza tumbles after sales miss, CEO retiring * Atos leads STOXX 600 after results Jan 30 - Welcome to the home for ...

  • Reuters - UK Focus

    LIVE MARKETS-It's gonna get better before it gets worse!

    * European stocks steady as trade talks loom * LVMH jumps, driving luxury stocks up * Lonza tumbles after sales miss, CEO retiring * Atos leads STOXX 600 after results Jan 30 - Welcome to the home for ...

  • Reuters - UK Focus

    LIVE MARKETS-Credit: How worried should European equity investors be?

    * European stocks steady as trade talks loom * LVMH jumps, driving luxury stocks up * Lonza tumbles after sales miss, CEO retiring * Atos leads STOXX 600 after results Jan 30 - Welcome to the home for ...

  • Associated Press

    Novartis: 4Q Earnings Snapshot

    The Basel, Switzerland-based company said it had net income of 51 cents per share. Earnings, adjusted for non-recurring costs, were $1.24 per share. The results missed Wall Street expectations. The average ...

  • Reuters - UK Focus

    LIVE MARKETS-Healthy pair: Long drugs, short STOXX

    * European stocks steady as trade talks loom * LVMH jumps, driving luxury stocks up * Lonza tumbles after sales miss, CEO retiring * Atos leads STOXX 600 after results Jan 30 - Welcome to the home for ...

  • Reuters - UK Focus

    LIVE MARKETS-Opening snapshot: LVMH lifts luxury; Lonza and Novartis tumble

    * European stocks falter as trade talks loom * LVMH jumps 6 pct, driving luxury stocks up * Lonza tumbles after sales miss, CEO retiring * Atos leads STOXX 600 after Jan 30 - Welcome to the home for real-time ...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more